Last updated: July 27, 2026
What is Acular (ketorolac tromethamine ophthalmic) and what clinical trials are still active or recently completed?
Acular is a topical ophthalmic NSAID (ketorolac tromethamine) used for pain and inflammation associated with ocular surgery and other ocular inflammatory conditions. Commercial competitiveness is driven less by platform novelty and more by (1) lifecycle extensions for formulations and dosing regimens, (2) manufacturing continuity, and (3) generic supply and labeling competition.
What clinical trial activity matters most for market projection?
For a marketed topical NSAID like Acular, market outcomes are typically influenced by:
- FDA labeling expansions or supplemental indications (rare, slow-moving)
- formulation changes that create line extensions (new NDA or supplement vs generic-substitutable equivalence)
- patent/litigation events that determine when 505(b)(2) or ANDA competitors can enter
For “clinical trials update” decision-making, the critical question is whether any trials translate into new labeling or meaningful differentiation versus generic substitutes already available.
Clinical trials update: data not provided
No specific source-backed details (trial IDs, statuses, enrollment, endpoints, dates, registrants, or sponsor statements) are included in the prompt. Without verifiable trial metadata, a complete and accurate update cannot be produced.
What is the current FDA regulatory status of Acular and how does Orange Book listing affect exclusivity?
Acular’s regulatory and exclusivity profile is determined by whether it is listed in FDA’s Orange Book (NDA and related patents and exclusivity codes). Market timing for generics depends on:
- patent expiration dates
- listed patent scope (drug substance, formulation, method of use)
- exclusivity periods (market exclusivity, pediatric exclusivity where applicable)
- any active patent litigation and settlement-triggered launch dates
Orange Book status: data not provided
No Orange Book listing details (NDA number, patent numbers, expiration dates, exclusivity codes, or listed dosage forms) are provided in the prompt. A complete, accurate exclusivity and generic-entry outlook cannot be produced without those listings.
When does Acular lose exclusivity and what is the projected generic launch risk?
The projected generic launch risk for Acular depends on:
- the last expiring Orange Book patent covering the marketed dosage form and labeling
- whether Paragraph IV challenges exist and have triggered litigation and settlements
- whether competing products use 505(b)(2) or ANDAs and how they map to the reference label
Exclusivity and launch timing: data not provided
The prompt provides no Orange Book patent expiration timeline, litigation docket, or settlement terms. A timeline-driven projection cannot be constructed.
How many patents protect Acular, what claims do they cover, and where are the likely barriers for generics?
Generic entry barriers for ophthalmic ketorolac typically arise from:
- formulation or particle/solubilization technologies that affect stability or bioavailability
- method-of-use claims tied to dosing schedules or post-operative regimens
- device/dosing system features if present (less common for simple solution products)
Patent estate mapping: data not provided
No patent list (publication numbers, assignees, jurisdictions, expiration dates) is included in the prompt. A quantified “how many patents” assessment with actionable filing or litigation implications cannot be produced.
What patent litigation affects Acular and what settlement outcomes exist?
For branded topical ophthalmics, litigation outcomes usually set:
- launch dates for Paragraph IV generics
- design-around claim strategies (different concentrations, dosing regimens, excipients)
- market allocation provisions in settlements
- triggers for FDA approval vs commercial launch
Litigation status: data not provided
No court cases, dockets, Paragraph IV certifications, or settlement announcements are included. A litigation-driven risk assessment cannot be completed.
How does Acular compare with ketorolac ophthalmic competitors and what is the likely competitive landscape?
Acular competes within ketorolac ophthalmic NSAIDs and adjacent post-surgical pain/inflammation regimens, including other NSAIDs and corticosteroid combinations depending on the prescriber pattern.
Market share outcomes typically follow:
- channel distribution strength (wholesaler access, contracting)
- formulary preference in managed care
- price compression after generic entry
- substitution rates driven by AB-rated generics
Comparative positioning: data not provided
The prompt provides no current competitor list, market share, pricing, or payer/formulary data. A defensible competitive landscape and projection cannot be generated.
What market size, revenue, and growth projections exist for Acular (ketorolac ophthalmic) by geography and channel?
An investable market projection requires, at minimum, one of:
- audited sales by strength and dosage form
- distributor/payer datasets or claims-based estimates
- credible syndicated sources with defined methodology and time series
Market metrics: data not provided
The prompt includes no revenue, units, prescriptions, pricing, or geography/channel breakdown. A complete market analysis and projection cannot be produced.
What could drive upside or downside for Acular over the next 3 to 5 years?
For an established topical NSAID, the principal drivers are:
- loss of reference protection and resulting price compression
- generic supply stability and backorders affecting shelf availability
- FDA enforcement actions or manufacturing recalls impacting availability
- label changes that alter prescriber behavior
- contracting and rebate changes in retail and institutional channels
Upside/downside scenario modeling: data not provided
Scenario inputs like exclusivity/expiration dates, projected generic entry, and current commercial performance are not provided.
Key Takeaways
- Acular is a marketed ophthalmic NSAID (ketorolac tromethamine), but the prompt does not include the regulatory, Orange Book, patent, litigation, clinical trial, or commercial datasets required to produce a complete, source-backed clinical trials update and market projection.
- A quantified exclusivity timeline, patent estate size, generic launch risk, and revenue outlook cannot be generated from the provided information.
FAQs
- What is the Orange Book patent and exclusivity profile for Acular ketorolac ophthalmic solution?
- Are there any Paragraph IV ANDA challenges filed for generic ketorolac ophthalmic products referenced to Acular?
- Which patent types (formulation, method-of-use, drug substance) most often restrict generic substitution for ophthalmic ketorolac?
- What clinical trial endpoints would most likely affect Acular labeling or differentiation versus AB-rated generics?
- How do post-cataract surgery NSAID prescribing patterns influence ketorolac ophthalmic sales and price erosion?
References
No sources were provided in the prompt.
